INVA
Price
$18.77
Change
-$0.29 (-1.52%)
Updated
Jul 11 closing price
Capitalization
1.18B
18 days until earnings call
SLNO
Price
$81.56
Change
-$6.92 (-7.82%)
Updated
Jul 11 closing price
Capitalization
4.3B
25 days until earnings call
Interact to see
Advertisement

INVA vs SLNO

Header iconINVA vs SLNO Comparison
Open Charts INVA vs SLNOBanner chart's image
Innoviva
Price$18.77
Change-$0.29 (-1.52%)
Volume$764.77K
Capitalization1.18B
Soleno Therapeutics
Price$81.56
Change-$6.92 (-7.82%)
Volume$2.53M
Capitalization4.3B
INVA vs SLNO Comparison Chart in %
Loading...
INVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INVA vs. SLNO commentary
Jul 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INVA is a StrongBuy and SLNO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 12, 2025
Stock price -- (INVA: $18.77 vs. SLNO: $81.57)
Brand notoriety: INVA and SLNO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INVA: 85% vs. SLNO: 281%
Market capitalization -- INVA: $1.18B vs. SLNO: $4.3B
INVA [@Biotechnology] is valued at $1.18B. SLNO’s [@Biotechnology] market capitalization is $4.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $318.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INVA’s FA Score shows that 1 FA rating(s) are green whileSLNO’s FA Score has 0 green FA rating(s).

  • INVA’s FA Score: 1 green, 4 red.
  • SLNO’s FA Score: 0 green, 5 red.
According to our system of comparison, SLNO is a better buy in the long-term than INVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INVA’s TA Score shows that 6 TA indicator(s) are bullish while SLNO’s TA Score has 2 bullish TA indicator(s).

  • INVA’s TA Score: 6 bullish, 5 bearish.
  • SLNO’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, INVA is a better buy in the short-term than SLNO.

Price Growth

INVA (@Biotechnology) experienced а -2.29% price change this week, while SLNO (@Biotechnology) price change was -5.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.14%. For the same industry, the average monthly price growth was +16.46%, and the average quarterly price growth was +20.75%.

Reported Earning Dates

INVA is expected to report earnings on Oct 29, 2025.

SLNO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLNO($4.3B) has a higher market cap than INVA($1.18B). SLNO YTD gains are higher at: 81.457 vs. INVA (8.184). INVA has higher annual earnings (EBITDA): 681K vs. SLNO (-194.63M). INVA has more cash in the bank: 447M vs. SLNO (290M). SLNO has less debt than INVA: SLNO (52.8M) vs INVA (451M). INVA has higher revenues than SLNO: INVA (370M) vs SLNO (0).
INVASLNOINVA / SLNO
Capitalization1.18B4.3B27%
EBITDA681K-194.63M-0%
Gain YTD8.18481.45710%
P/E Ratio51.97N/A-
Revenue370M0-
Total Cash447M290M154%
Total Debt451M52.8M854%
FUNDAMENTALS RATINGS
INVA vs SLNO: Fundamental Ratings
INVA
SLNO
OUTLOOK RATING
1..100
5317
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
5839
SMR RATING
1..100
9398
PRICE GROWTH RATING
1..100
5839
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INVA's Valuation (74) in the Pharmaceuticals Other industry is in the same range as SLNO (100) in the Medical Specialties industry. This means that INVA’s stock grew similarly to SLNO’s over the last 12 months.

SLNO's Profit vs Risk Rating (39) in the Medical Specialties industry is in the same range as INVA (58) in the Pharmaceuticals Other industry. This means that SLNO’s stock grew similarly to INVA’s over the last 12 months.

INVA's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as SLNO (98) in the Medical Specialties industry. This means that INVA’s stock grew similarly to SLNO’s over the last 12 months.

SLNO's Price Growth Rating (39) in the Medical Specialties industry is in the same range as INVA (58) in the Pharmaceuticals Other industry. This means that SLNO’s stock grew similarly to INVA’s over the last 12 months.

INVA's P/E Growth Rating (2) in the Pharmaceuticals Other industry is significantly better than the same rating for SLNO (100) in the Medical Specialties industry. This means that INVA’s stock grew significantly faster than SLNO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INVASLNO
RSI
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
63%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
60%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
61%
Bullish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 9 days ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
INVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FOSFX75.22N/A
N/A
Fidelity Overseas
GSTSX10.69N/A
N/A
Goldman Sachs Strategic Growth Svc
STTIX9.23N/A
N/A
North Square Core Plus Bond I
HCMSX30.43N/A
N/A
HCM Tactical Growth R
STVZX10.62N/A
N/A
Virtus Ceredex Large-Cap Value Equity R6